Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

NCT00035178 | Completed Phase 4

• 1 other identifier: ARG-402
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 2

Brief Summary

The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.

Conditions

Kidney Failure, Chronic; Renal Disease, End-Stage

Keywords

ESRD; End-stage renal disease; Hemodialysis

Interventions

Argatroban DRUG

Eligibility Criteria

• Age: 21 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients, adult men or women who are between 21 and 75 years of age who are on maintenance hemodialysis regimen for at least three (3) months prior to the study start.
• Patients who can tolerate a hemodialysis session lasting up to 9 hours.
• Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per minute.
• Female volunteers who are not documented to be surgically sterile must be willing to abstain from sexual intercourse during the study or be willing to use intrauterine devices or 2 forms of barrier contraception for at least 7 days prior to the initial dose of study medication and continuing through the completion of the study.

You may not qualify if:

• Any clinically relevant abnormality identified per the investigator on the screening medical assessment or laboratory examination.
• History of regular alcohol abuse.
• Treatment with an investigational drug within 30 days.
• History of drug allergy of clinical significance in the opinion of the investigator.
• Currently taking warfarin or other anticoagulants.
• Currently taking NSAIDs (with the exception of aspirin).
• Individuals who are obese.
• Any history of bleeding disorder.
• Any subject with a screening resting systolic blood pressure \>180 mmHg and/or resting diastolic blood pressure of \>100 mmHg unless, in the opinion of the principal investigator, the blood pressures would not endanger the subject while participating in this trial.
• Concurrent uncontrolled cardiovascular, hematologic, respiratory, CNS, gastrointestinal disease or chronic alcoholism.
• Anemia defined as a hematocrit of \< 30 and hemoglobin \< 10g/dL.
• Concurrently taking (within the past 30 days) phenytoin, cimetidine, rifampin, cyclosporin or tacrolimus.
• Known hypersensitivity to Argatroban or related compounds.
• Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range.

Sponsors & Collaborators

• Texas Biotechnology Corporation: lead

Study Sites (2)

University of Chicago, Section of Nephrology

Chicago, Illinois, 60637, United States

Location

DaVita Clinical Research

Minneapolis, Minnesota, 55404, United States

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Interventions

argatroban

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: May 2, 2002
• First Posted: May 3, 2002
• Study Start: May 1, 2002
• Study Completion: November 1, 2002
• Last Updated: June 24, 2005

Record last verified: 2003-12

Locations

US (2)